iRhythm

By Jonah Comstock October 20, 2016
iRhythm, the wearable heart monitor company that announced its intention to IPO last month, went public today and increased its share price and number of shares on offer, raising the value of its IPO from an expected $86 million to $107 million. The company is offering 6,294,118 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts. Underwriters...
By Jonah Comstock September 26, 2016
iRhythm, maker of the wearable-and-wireless-but-not-connected Zio heart rate monitoring system, has filed with the SEC to raise up to $86 million in an initial public offering.  The Zio patch, iRhythm's sole product as of now, is a small wearable sensor, used for multi-day monitoring of arrhythmias in cardiac patients (up to a fortnight). Unlike many participants in that space, however, the...
By Jonah Comstock November 30, 2015
The Scripps Translational Science Institute is working with Aetna and Johnson & Johnson to launch a trial that will test iRhythm's Zio Patch and the Amiigo activity tracker as possible new ways to screen at-risk populations for atrial fibrillation. "What we really want at the end of this study is to be able to best understand what the right way is to screen high-risk patients for atrial...
By Jonah Comstock May 18, 2015
Research firm Tractica predicts that worldwide unit shipments of clinical and non-clinical connected wearable patches will grow to 12.3 million per year by 2020. Last year, annual shipments were just 67,000. The market for such connected patches, Tractica predicts, will hit $3.3 billion per year. Tractica describes the category as including "patches, tattoos, or small devices that are affixed to...
By Jonah Comstock May 22, 2014
iRhythm Technologies, maker of the Zio patch peel-and-stick heart monitor, has raised $17 million in a round led by Novo A/S, a Danish life sciences investment firm. Previous investor Norwest Venture Partners also participated in the round. This brings the company's total disclosed funding to about $85 million, based on SEC filings and company announcements. As part of the latest investment deal...
By Jonah Comstock January 31, 2014
Aetna will now reimburse for iRhythm's ZIO Patch, a continuous long-term heart monitor worn on an adhesive patch. The insurer recently updated its Clinical Policy Bulletin on cardiac event monitors, upgrading the ZIO Patch from "experimental and investigational" to "medically necessary" for certain conditions. In particular, Aetna will reimburse for the ZIO Patch either "to evaluate syncope or...
By Jonah Comstock January 3, 2014
A new study from the Scripps Translational Science Institute, published in the American Journal of Medicine, shows that iRhythm's Zio patch, a wireless adhesive heart monitor patch, detects more arrhythmia events than a traditional Holter monitor and provides a better experience for patients. The study of 146 patients with mild atrial fibrillation compared the two devices over the length of time...
By Aditi Pai May 23, 2013
Over the course of the past few weeks, various digital health companies have raised funds. The roundup below includes investment news from companies that offer a range of digital health products and services, including online physician visits, non-invasive medical sensors, snail mail-powered remote monitoring devices, and portable blood test devices. ConsultingMD $10 million: Palo Alto,...
By Neil Versel November 26, 2012
The California HealthCare Foundation (CHCF) has invested $1.5 million in iRhythm Technologies, maker of Zio Patch, an FDA-cleared ambulatory cardiac rhythm monitor. The Oakland, Calif.-based foundation also says it will sponsor studies of the technology at two safety-net health systems in the state. Zio Patch differs from many other wearable monitors in that it does not have built-in wireless...
By Brian Dolan May 18, 2010
St. Jude Medical and iRhythm Technologies have inked a deal to co-market iRhythm's Zio Patch, an wearable, single-use continuous ambulatory cardiac rhythm monitor. The Zio patch recently received 510(k) clearance from the FDA and is prepping for a commercial launch in the US, which is where the company's new cash infusion comes in: iRhythm also announced a $10 million round of financing that was...

Editor's Pick